Manchikanti L, Grow J B, Colliver J A, Hadley C H, Hohlbein L J
Anesthesiology. 1985 Oct;63(4):378-84. doi: 10.1097/00000542-198510000-00006.
To evaluate the effect of Bicitra (Willen Drug Company, Baltimore, Maryland), a commercial preparation of sodium citrate and metoclopramide, on gastric contents 150 elective outpatients allocated into six groups with 25 patients in each group were studied. Patients in Group 1 served as controls. Patients in Groups 2, 3, 5, and 6 received Bicitra, po, either 15 ml (Groups 2 and 5) or 30 ml (Groups 3 and 6). In addition, patients in Groups 5 and 6 also received metoclopramide 10 mg, iv; Group 4 patients received metoclopramide 10 mg, iv. Eighty-eight per cent of patients in the control group had a gastric pH less than or equal to 2.5, while 36% had a gastric content volume greater than or equal to 25 ml with pH less than or equal to 2.5. Bicitra, 15 ml and 30 ml, po, increased mean gastric pH and decreased the proportion of patients with a gastric pH less than or equal to 2.5 to 32 and 16%, respectively, in Groups 2 and 3. However, Bicitra 15 ml and 30 ml, increased the mean gastric volume in Group 3 and also increased the proportion of patients with a gastric volume greater than or equal to 25 ml to 56% in Group 2 and 84% in Group 3. The addition of metoclopramide 10 mg, iv, to Bicitra reduced the proportion of patients with a gastric volume greater than or equal to 25 ml in Groups 5 and 6 to 28 and 36%, respectively. Metoclopramide (Group 6) independently reduced mean gastric volume (15.6 ml vs. 32.7 ml) and the proportion of patients with a gastric volume greater than or equal to 25 ml (20% vs. 36%). Bicitra and metoclopramide combination significantly reduced the proportion of patients with gastric contents greater than or equal to 25 ml with pH less than or equal to 2.5.
为评估枸橼酸钠和甲氧氯普胺的商业制剂Bicitra（威伦制药公司，马里兰州巴尔的摩）对胃内容物的影响，对150名择期门诊患者进行了研究，将其分为6组，每组25名患者。第1组患者作为对照。第2、3、5和6组患者口服Bicitra，剂量分别为15 ml（第2和5组）或30 ml（第3和6组）。此外，第5和6组患者还静脉注射10 mg甲氧氯普胺；第4组患者静脉注射10 mg甲氧氯普胺。对照组中88%的患者胃pH值小于或等于2.5，而36%的患者胃内容物体积大于或等于25 ml且pH值小于或等于2.5。口服15 ml和30 ml的Bicitra可提高平均胃pH值，并将胃pH值小于或等于2.5的患者比例分别降至第2组和第3组的32%和16%。然而，15 ml和30 ml的Bicitra增加了第3组的平均胃体积，并将胃体积大于或等于25 ml的患者比例分别提高到第2组的56%和第3组的84%。在Bicitra中添加静脉注射10 mg甲氧氯普胺可将第5和6组中胃体积大于或等于25 ml的患者比例分别降至28%和36%。甲氧氯普胺（第6组）可独立降低平均胃体积（15.6 ml对32.7 ml）和胃体积大于或等于25 ml的患者比例（20%对36%）。Bicitra与甲氧氯普胺联合使用可显著降低胃内容物大于或等于25 ml且pH值小于或等于2.5的患者比例。
